Ciclesonide: A safe and effective inhaled corticosteroid for the treatment of asthma

Journal of Asthma and Allergy

Volumn , Issue 2, 2009, Pages 25-32

  Schaffner, Timothy J ^a,b   Skoner, David P ^a,b,c  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Asthma; Ciclesonide; Inhaled corticosteroid

Indexed keywords

ADENOSINE PHOSPHATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; DESISOBUTYRYLCICLESONIDE; DRUG METABOLITE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; NITRIC OXIDE; PLACEBO; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHILD GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE CONTROL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GROWTH RATE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; METERED DOSE INHALER; PHARYNGITIS; PLASMA PROTEIN BINDING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY; REVIEW; THRUSH;

EID: 77953466947     PISSN: None     EISSN: 11786965     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Fuhlbrigge AL, Adams RJ, Guillbert TW, et al. The burden of asthma in the United States. Am J Repir Crit Care Med. 2002;166:1044-1049.
2. Kivity S, Shochat Z, Bressler R, Wiener M, Lerman Y. The characteristics of bronchial asthma among a young adult population. Chest. 1995;108:24-27.
3. Akinbami L. The state of childhood asthma, United States 1980-2005. Advance data from vital and health statistics; no 381, Hyattsville, MD: National Center for Health Statistics. 2006.
4. Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma - United States 1980-1999. MMWR Surveill Summ. 2002. Mar 29;51(1):1-13.
5. National Asthma Education and Prevention Program. NAEPP Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma - Full Report 2007. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute; August 2007.
6. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2007. Available from: http://www.ginasthma.org.
7. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol. 1995;95(1pt 1):29-33.
8. Shapiro G, Mendelson L, Kraemer M, Cruz-Rivera M, Walton- Bowen K, Smith JA. Efficacy and safety of budesonide inhalation suspension in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol. 1998;102:789-796. (Pubitemid 28543529)
9. Skoner DP. Balancing safety and efficacy in pediatric asthma management. Pediatrics. 2002;109(2 suppl):381-392. (Pubitemid 34126852)
10. Becker AB, Kuznetsova O, Vermeulen J, et al. Pediatric Montelukast Linear Growth Study Group. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Ann Allergy Asthma Immunol. 2006;96(6):800-807.
11. Simons FE. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. N Engl J Med. 1997;337(23):1659-1665.
12. Hanania NA, Chapman KR, Sturtridge WC, et al. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol. 1995;96(5Pt 1):571-579.
13. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001;345(13):941-947. (Pubitemid 34940809)
14. Zollner EW. Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids (Part 2) - the risk as determined by gold standard adrenal function tests: a systematic review. Pediatr Allergy Immunol. 2007;18(6):469-474.
15. Chrousos GP, Ghaly L, Shedden A, Iezzoni DG, Harris AG. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest. 2005;128(1):70-77. (Pubitemid 40994456)
16. Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid- induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol. 2007;98(3):225-238. (Pubitemid 46417568)
17. Fukushima C, Matsuse H, Saeki S, et al. Salivary IgA and oral candidiasis in asthmatic patients treated with inhaled corticosteroid. J Asthma. 2005;42(7):601-604. (Pubitemid 41765313)
18. Stoeck M, Riedel R, Hochhaus G, et al. In vitro and in vivo antiinflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther. 2004;309:249-258. (Pubitemid 38393137)
19. Christie P. Ciclesonide: A novel inhaled corticosteroid for asthma. Drugs Today (Barc). 2004;40(7):569-576. (Pubitemid 39281174)
20. Nave R, Drollman A, Meyer W, Zech K. In vivo epimeric stability of ciclesonide. Am J Respir Crit Care Med. 2003;167:Abstract A1485.
21. Nave R, Gunawardena KA, Zech K, Bethke TD. Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyrylciclesonide in healthy subjects and patients with asthma are similar. Int J Clin Pharm Ther. 2006;44(1)1-7. (Pubitemid 43085491)
22. Drollmann A, Nave R, Steinijans VW, Baumgartner E, Bethke TD. Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation. Clin Pharmacokinet. 2006;45:729-736. (Pubitemid 43990573)
23. Nave R, Fisher R, Zech K. In vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharm Drug Dispos. 2006;27:197-207. (Pubitemid 43797116)
24. Nave R, Fischer R, McCracken N. In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices. Respir Res. 2007;8:65.
25. 14C]-Ciclesonide after oral administration to healthy subjects. Clin Pharmacokinet. 2004;43(7)479-486.
26. Drollman A, Hasselquist BE, Boudreau RJ, et al. Ciclesonide shows high lung deposition in 2D and 3D-imaging. Am J Respr Crit Care Med. 2002;165:Abstract A40.
27. Rohtagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol. 2003;43:365-378.
28. Leach C, Bethke T, Boudreau R. 2-D and 3-D imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med. 2006;19:117-126.
29. Nave R, Sato H, Nonaka T, Mochiduki T, Takahama S, Kondo S. Uptake, retention and metabolism of ciclesonide in human alveolar epithelial cells. Eur Respir J. 2005;26(suppl 49):255s.
30. Reynolds RA, Scott LJ. Ciclesonide. Drugs. 2004;64(5):511-519.
31. Dahl R, Nielsen LP, Christensen MB, Engelstätter R. Ciclesonide - an inhaled corticosteroid prodrug - inhibits allergen induced early and late phase reactions. Eur Respir J. 1998;12(suppl 28):26s. Abstract P0475.
32. Nonaka T, Sugiyama H, Taneda M, et al. Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro. Eur Respir J. 2002;20(suppl 38): Abstract P652.
33. Wilson AM, Duong M, Pratt B, Dolovich M, O'Byrne PM. Antiinflammatory effects of once daily low dose inhaled ciclesonide in mild to moderate asthmatic patients. Allergy. 2006;61:537-542.
34. Bateman E, Karpel J, Casale T, Wenzel S, Banerji D. Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest. 2006;129:1176-1187.
35. O'Connor BJ, Kilfeather S, Cheung D, et al. Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks. Eur Respir J. 2002;20(suppl 38):Abstract 2579.
36. Langdon CG, Adler M, Mehra S, Alexander M, Drollman A. Once-daily ciclesonide is safe and effective in patients with persistent asthma. Respir Med. 2005;99:1275-1285.
37. Chapman KR, Patel P, D'Urzo AD, et al. Maintenance of asthma control by once-daily ciclesonide in adults with persistent asthma. Allergy. 2005;60:330-337.
38. Gelfand EW, Georgitis JW, Noonan M, Ruff ME. Once-daily ciclesonide in children: efficacy and safety in asthma. J Pediatr. 2006;148:377-383.
39. Postma DS, Sevette C, Martinat Y, Schlösser N, Aumann J, Kafé H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J. 2001;17:1083-1088. (Pubitemid 32717462)
40. Knox A, Langan J, Martinot JB, Gruss C, Häfner D. Comparison of a step-down dose of once-daily ciclesonide with a continued dose of twice-daily fluticasone propionate in maintaining control of asthma. Curr Med Res Opin. 2007;23(10):2387-2394. (Pubitemid 350033440)
41. Lee DK, Haggart K, Currie GP, Bates CE, Lipworth BJ. Effects of hydroflouroalkane formulations of ciclesonide 400 μg once daily vs fluticasone 250 μg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br J Clin Pharm. 2004;58(1):26-33. (Pubitemid 38901463)
42. Buhl R, Vinkler I, Magyar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther. 2006;19(6):404-412. (Pubitemid 44234118)
43. Ukena D, Biberger C, Steinijans V, et al. Ciclesonide is more effective than budesonide in the treatment of persistent asthma. Pulm Pharmacol Ther. 2007;20(5):562-570. (Pubitemid 47077649)
44. Niphadkar P, Jagannath K, Joshi JM, et al. Comparison of the efficacy of ciclesonide 160 μg QD and budesonide 200 μg BID in adults with persistent asthma: A phase III, randomized, double-dummy, open-label study. Clin Ther. 2005;27(11):1752-1763. (Pubitemid 41815226)
45. Boulet LP, Drollman A, Magyar P, et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med. 2006;100:785-794.
46. Hansel TT, Benezet O, Kafé H, et al. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin Ther. 2006;28(6):906-920. (Pubitemid 44062700)
47. von Berg A, Engelstätter R, Minic P, et al. Comparison of the efficacy and safety of ciclesonide 160 μg once daily vs. budesonide 400 μg once daily in children with asthma. Pediatr Allergy Immunol. 2007;18:391-400. (Pubitemid 47037911)
48. Vermeulen JH, Gyurkovits K, Rauer H, Engelstätter R. Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respir Med. 2007;101(10):2182-2191. (Pubitemid 47336868)
49. Boulet LP, Bateman ED, Voves R, Müller T, Wolf S, Engelstätter R. A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respir Med. 2007;101(8):1677-1686. (Pubitemid 46930712)
50. Bateman ED, Linnhof AE, Homik L, Freudensprung U, Smau L, Engelstätter R. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther. 2008;21(2):264-275. (Pubitemid 351312669)
51. Pedersen S, Garcia Garcia ML, Manjra AI, Theron I, Engelstätter R. A comparative study of inhaled ciclesonide 160 μg/day and fluticasone propionate 176 μg/day in children with asthma. Pediatr Pulmonol. 2006;41(10):954-961. (Pubitemid 44534813)
52. Richter K, Kanniess F, Biberger C, Nave R, Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol. 2005;45:146-152. (Pubitemid 40490437)
53. Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydroflouroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol. 2005;61:203-208. (Pubitemid 40768553)
54. Pearlman DS, Berger WE, Kerwin E, LaForce C, Kundu S, Banerji D. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol. 2005;116:1206-1212. (Pubitemid 41740924)
55. Agertoft L, Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol. 2005;115:940-945. (Pubitemid 40616206)
56. Szefler S, Rohatagi S, Williams J, Lloyd M, Kundu S, Banerji D. Ciclesonide, a novel inhaled steroid, does not affect hypthalamic-pituitary- adrenal axis function in patients with moderate-to-severe persistent asthma. Chest. 2005;128:1104-1114. (Pubitemid 41324383)
57. Lipworth BJ, Kaliner MA, LaForce CF, Baker JW, Kaiser HB, Amin D, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol. 2005;94:465-472. (Pubitemid 40547935)
58. Derom E, Van De Velde V, Marissens S, Engelstätter R, Vincken W, Pauwels R. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm Pharmacol Ther. 2005;18(5):328-336. (Pubitemid 40804531)
59. Skoner DP, Maspero J, Banerji D, and the Ciclesonide Pediatric Growth Study Group. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics. 2008;121(1):e1-14.
60. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343(15):1064-1069. (Pubitemid 30761077)
61. Rohatagi S, Luo Y, Shen L, Guo Z, Schemm C, Huang Y, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther. 2005;12(3):201-209. (Pubitemid 40825123)
62. Nave R, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther. 2005;18:390-396. (Pubitemid 41354264)